Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.55 |
| ▸ | CCND1 | P24385 | 4/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052509 | 0.98 | CDK4 (0.57) | CDK4CCND1RAD52ABCB1HTR6 | |
| SCHEMBL4828100 | 0.95 | CDK4 (0.57) | CDK4CCND1RAD52ABCB1HTR6 | |
| SCHEMBL12543448 | 0.84 | CDK4 (0.69) | CDK4CCND1RAD52ABCB1HTR6 | |
| SCHEMBL3205345 | 0.83 | CDK4 (0.56) | CDK4CCND1ABCB1HTR6HTR2A | |
| SCHEMBL30041985 | 0.83 | CDK4 (0.52) | CDK4CCND1RAD52HTR6KMT2A | |
| SCHEMBL5944315 | 0.83 | CDK4 (0.52) | CDK4CCND1HTR6KMT2AHTR2A | |
| SCHEMBL3205958 | 0.83 | CDK4 (0.52) | CDK4CCND1RAD52HTR6KMT2A | |
| SCHEMBL3990185 | 0.82 | CDK4 (0.71) | CDK4CCND1RAD52ABCB1HTR6 | |
| SCHEMBL29780338 | 0.82 | CDK4 (0.71) | CDK4CCND1RAD52ABCB1HTR6 | |
| Ammonia Solution, Strong SCHEMBL28783985 | 0.81 | CDK4 (0.55) | CDK4CCND1ABCB1HTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410075-B2 | Mannich base N-oxide drugs | CASCADE PRODRUG INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410075-B2 | Mannich base N-oxide drugs | CASCADE PRODRUG INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| US-20080027072-A1 | Potentiation of MC4 receptor activity | AMPLA PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-4358456-A | Antipsychotic piperidinomethyl-indole derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1982-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027072-A1 | Potentiation of MC4 receptor activity | MC4R, MC5R, MC2R | CDK4 2925/4885CCND1 4494/4885RAD52 4256/4885 |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | ASAH2, MAN2B1, NNT | CDK4 2781/4885CCND1 4181/4885RAD52 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.